Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 5/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728677 | 0.88 | TRPV1 (0.47) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL17728678 | 0.88 | TRPV1 (0.47) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL1704680 | 0.85 | ALDH1A1 (0.59) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL380969 | 0.85 | ALDH1A1 (0.61) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL12041869 | 0.85 | MAPT (0.64) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL17941592 | 0.85 | TRPA1 (0.50) | ARTRPA1 | |
| SCHEMBL28222847 | 0.84 | AR (0.46) | ARTRPA1 | |
| SCHEMBL4507709 | 0.84 | PTPN2 (0.50) | NPC1RAB9AGPR119ARPTPN2 | |
| SCHEMBL13158349 | 0.84 | ALDH1A1 (0.60) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL29665918 | 0.83 | AR (0.48) | ARTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247701-B1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3145925-B1 | ANTHELMINTIC COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10463661-B2 | Anthelmintic compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3428162-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10155725-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180338972-A1 | ANTHELMINTIC COMPOUNDS | MERIAL INC. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081697-A2 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | ALDH1A1 864/4885MAPT 1648/4885NPC1 1384/4885 |
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | CYP8B1, CYP2C8, CYP2B6 | ALDH1A1 1300/4885MAPT 4845/4885NPC1 1401/4885 |
| US-10463661-B2 | Anthelmintic compounds | HRH4, QTRT1, Q6ZSR9 | ALDH1A1 3036/4885MAPT 4826/4885NPC1 2700/4885 |
| US-10155725-B2 | Anthelmintic compounds and compositions and method of using thereof | CYP3A5, ABCC5, CXXC5 | ALDH1A1 2176/4885MAPT 4784/4885NPC1 2184/4885 |
| US-20180338972-A1 | ANTHELMINTIC COMPOUNDS | HRH4, QTRT1, Q6ZSR9 | ALDH1A1 3036/4885MAPT 4826/4885NPC1 2700/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | ALDH1A1 2176/4885MAPT 4784/4885NPC1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.